
Colorectal cancer (CRC) is the leading cause of cancer death; however, targets with broad anti-CRC effects are limited. Sirtuin6 (SIRT6) is a conserved nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase that is widely pathologically downregulated in CRC.
MDL-811, an allosteric SIRT6 activator, enhances SIRT6 deacetylation.
Pharmacokinetic studies were performed by Medicilon, following standard protocols.

Reference:
相关新闻